Following the completion of Thermo Fisher Scientific’s TMO controversial and long-speculated acquisition of Affymetrix Inc., the company is once again in the headlines owing to its new strategic alliance with Siemens Healthcare. This latest deal will boost Thermo Fisher’s molecular testing wing by integrating the company’s real-time PCR system into Siemens’ VERSANT kPCR Molecular Solution.Thermo Fisher’s real-time PCR instruments are easy to use. These are designed for mid-throughput and provide ideal solutions for all users who need a high-performance instrument with features for maximum experiment control. The partnership will also offer Siemens’ complete molecular testing solution to the laboratories. Siemens will display the entire system at the European Congress of Clinical Microbiology and Infectious Disease in Amsterdam, from April 9–12, 2016.According to both the companies, this will bring a new level of innovation to the market by providing more flexibility and customization to the molecular laboratory workflow. According to Thermo Fisher, this will further brace the company’s forte in the field of diagnostics space.Thermo Fisher, of late, has formed several alliances across the world to boost its performance in the field of diagnostics and applied market. One such example is its collaboration with the Karolinska Institute of Sweden, on a groundbreaking clinical study aimed at developing a more effective test for prostate cancer.Using Thermo Fisher’s proteomic, genomic and assay technologies, this test can predict, or more precisely, distinguish between benign and aggressive cancers, thus reducing the number of biopsies required without compromising the number of actual cancers diagnosed.The company is optimistic that its performance in diagnostics and healthcare will be slightly better in 2016. The latest partnership with Siemens Health should contribute to this end.Thermo Fisher currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the medical sector are Accuray Incorporated ARAY, AngioDynamics Inc. ANGO and Edwards Lifesciences Corp. EW. All the three stocks carry a Zacks Rank #2 (Buy).Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report THERMO FISHER (TMO): Free Stock Analysis Report ACCURAY INC (ARAY): Free Stock Analysis Report ANGIODYNAMICS (ANGO): Free Stock Analysis Report EDWARDS LIFESCI (EW): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research